Antihistamines for allergic rhinitis
DOI: 10.32364/2587-6821-2020-4-1-26-30
N.V. Shartanova, E.F. Glushkova, O.I. Sidorovich
NRC Institute of Immunology, Moscow, Russian Federation
The growing prevalence of allergic disorders in human population in recent decade has prompted the World Health Organization to proclaim 21st century to be “the century of allergy”. Allergic rhinitis (AR) is one of the most prevalent allergies being a global medical social issue. This is accounted for by its high prevalence among children, adolescents, and adults. Poor quality of life is also important since these patients have to consult a variety of specialists before they visit allergist.
The role of antihistamines for allergic diseases cannot be overestimated. AR is no exception since this disorder is a component of systemic inflammation. Therefore, systemic antihistamines are the first-line choice for AR.
This article summarizes recent global data on AR treatment, in particular, antihistamines. Results from current studies on levocetirizine as compared with the effects of other molecules on seasonal AR are addressed.
Keywords: levocetirizine, antihistamine therapy, H1 antagonists, allergic rhinitis, allergy.
For citation: Shartanova N.V., Glushkova E.F., Sidorovich O.I. Antihistamines for allergic rhinitis. Russian Medical Review. 2020;4(1):26–30. DOI: 10.32364/2587-6821-2020-4-1-26-30.
About the authors:
Nataliya V. Shartanova — MD, PhD, Head of the Outpatient Department, ORCID iD 0000-0002-1197-9002;
Evgeniya F. Glushkova — MD, allergist and immunologist of the Outpatient Department, ORCID iD 0000-0002-4908-6146;
Ol’ga I. Sidorovich — MD, PhD, Senior Researcher of the Research Consultative Department, ORCID iD 0000-0003-1000-0664.
NRC Institute of Immunology. 24, Kashirskoe road, Moscow, 115478, Russian Federation.
Contact information: Evgeniya F. Glushkova, e-mail: glushkovaef@gmail.com. Financial Disclosure: no authors have a financial or property interest in any material or method mentioned. There is no conflict of interests. Received 25.03.2020.
References
1. Гущин И.С., Ильина Н.И., Польнер С.А. Аллергический ринит. Пособие для врачей. ГНЦ Институт иммунологии, РААКИ. М.; 2002. [Guschin I.S., Ilina N.I., Polner S.A. Allergic rhinitis: a manual for doctors. Institute of immunology, RAACI. M.; 2002 (in Russ.)].
2. Brożek J.L., Bousquet J., Agache I. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines — 2016 revision. J Allergy Clin Immunol. 2017;140(4):950–958. DOI: 10.1016/j.jaci.2017.03.050.
3. Bousquet J., Khaltaev N., Cruz A.A. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen. Allergy. 2008;(63):8–160.
4. Gregory C., Cifaldi M., Tanner L.A. Targeted intervention programs: creating a customized practice model to improve the treatment of allergic rhinitis in a managed care population. Am J Manag Care. 1999;5:485–496.
5. Носуля Е.В., Ким И.А. Современные стратегии лечения аллергического ринита. Вестник оториноларингологии. 2016;(2):74–76. [Nosulya E.V., Kim I.A. Current treatment strategies for allergic rhinitis. Vestnik otolaringologii. 2016;(2):74–76 (in Russ.)].
6. De Greve G., Hellings P.W., Fokkens W.J. et al. Endotype-driven treatment in chronic upper airway diseases. Clin Transl Allergy. 2017;7:22. DOI: 10.1186/s13601-017-0157-8.
7. Amaral R., Fonseca J.A., Jacinto T. et al. Having concomitant asthma phenotypes is common and independently relates to poor lung function in NHANES 2007–2012. Clin Transl Allergy. 2018;8:13. DOI: 10.1186/s13601-018-0201-3.
8. Cingi C., Gevaert P., Mosges R. et al. Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology Task Force Report. Clin Transl Allergy. 2017;7:17. DOI: 10.1186/s13601-017-0153-z.
9. ARIA in the pharmacy: management of allergic rhinitis symptoms in the pharmacy. Allergic rhinitis and its impact on asthma. Allergy. 2004;59(4):373–387. DOI: 10.1111/j.1398-9995.2003.00468.x.
10. Carr W.W., Yawn B.P. Management of allergic rhinitis in the era of effective over-the-counter treatments. Postgrad Med. 2017;129(6):572–580. DOI: 10.1080/00325481.2017.1333384.
11. Lombardi C., Musicco E., Rastrelli F. et al. The patient with rhinitis in the pharmacy. A cross-sectional study in real life. Asthma Res Pract. 2015;1(1):4. DOI: 10.1186/s40733-015-0002-6.
12. Fromer L.M., Blaiss M.S., Jacob-Nara J.A. et al. Current Allergic Rhinitis Experiences Survey (CARES): Consumers’ awareness, attitudes and practices. Allergy Asthma Proc. 2014;35(4):307–315. DOI: 10.2500/aap.2014.35.3766.
13. Bousquet J., Neukirch F., Bousquet P.J. et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol. 2006;117(1):158–162. DOI: 10.1016/j.jaci.2005.09.047.
14. Bousquet J., Annesi-Maesano I., Carat F. et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin Exp Allergy. 2005;35(6):728–732. DOI: 10.1111/j.1365-2222.2005.02274.x.
15. Bousquet P.J., Devillier P., Tadmouri A. et al. Clinical relevance of cluster analysis in phenotyping allergic rhinitis in a real-life study. Int Arch Allergy Immunol. 2015;166(3):231–240. DOI: 10.1159/000381339.
16. Del Cuvillo A., Montoro J., Bartra J. et al. Validation of ARIA duration and severity classifications in Spanish allergic rhinitis patients — the ADRIAL cohort study. Rhinology. 2010;48(2):201–205. DOI: 10.4193/Rhin09.099.
17. Jauregui I., Davila I., Sastre J. et al. Validation of ARIA (Allergic Rhinitis and its Impact on Asthma) classification in a pediatric population: the PEDRIAL study. Pediatr Allergy Immunol. 2011;22(4):388–392. DOI: 10.1111/j.1399-3038.2010.01108.x.
18. Leynaert B., Bousquet J., Neukirch C. Perennial rhinitis: an independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey. J Allergy Clin. Immunol. 1999;(104):301–304. DOI: 10.1016/S0091-6749(99)70370-2.
19. Gergen P.J., Turkeltaub P.C. The association of individual allergen reactivity with respiratory disease in a national sample: data from the second National Health and Nutrition Examination Survey, 1976–80 (NHANES II). J Allergy Clin Immunol. 1992;(90):579–588. DOI: 10.1016/0091-6749(92)90130-T.
20. Pedersen P.A., Weeke E.R. Asthma and allergic rhinitis in the same patients. Allergy. 1983;(38):25–29. DOI: 10.1111/j.1398-9995.1983.tb00852.x.
21. Greisner W.A., Settipane R.J., Settipane G.A. Co-existence of asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Asthma Proc. 1998;(19):185–188. DOI: 10.2500/108854198778557836.
22. Guerra S., Sherrill D.L., Baldacci S. Rhinitis is an independent risk factor for developing cough apart from colds among adults. Allergy. 2005;(60):343–349. DOI: 10.1111/j.1398-9995.2005.00717.x.
23. Хаитов Р.М., Ильина Н.И. Аллергология и иммунология: национальное руководство. М.: ГЭОТАР-Медиа; 2009. [Haitov R.M., Il’ina N.I. Allergologija i immunologija: nacional’noe rukovodstvo. M.: GJEOTAR-Media; 2009 (in Russ.)].
24. Cauwenberge P., Bachert C., Passlacqua G. et al. Consensus statement on the treatment of allergic rhinitis. Allergy. 2000;55:116–134. DOI: 10.1034/j.1398-9995.2000.00526.x.
25. Ильина Н.И., Курбачева О.М., Павлова К.С., Польнер С.А. Федеральные клинические рекомендации. Аллергический ринит. Российский аллергологический журнал. 2018;(4):43–53. [Ilina N.I., Kurbacheva O.M., Pavlova K.S., Polner S.A. Federal Clinical Recommendations. Allergic rhinitis. Russian Journal of Allergy. 2018;(4):43–53 (in Russ.)].
26. Пискунов Г.З., Пискунов С.З. Клиническая ринология: руководство для врачей. М.: Миклош; 2002. [Piskunov G.Z., Piskunov S.Z. Clinical Rhinology: A Guide for Physicians. M.: Miklosh; 2002 (in Russ.)].
27. Лопатин А.С. Ринит. М.: Литера; 2010. [Lopatin A.S. Rhinitis. M.: Litera; 2010 (in Russ.)].
28. Bousquet J., Schünemann H.J., Hellings P.W. et al. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol. 2016;138:367–374. DOI: 10.1016/j.jaci.2016.03.025.
29. Bousquet J., van Cauwenberge P., Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001:(108);147–334. DOI: 10.1067/mai.2001.118891.
30. Лусс Л.В., Ильина Н.И. Антигистаминные препараты в общеклинической практике. Вопросы и ответы. М.: Медицинское информационное агентство; 2017. [Luss L.V., Ilyina N.I. Antihistamines in general clinical practice. Questions and answers. M.: Medical News Agency; 2017 (in Russ.)].
31. Church M., Church D. Pharmacology of antihistamines. Indian J dermatol. 2013:(58):219–224. DOI: 10.4103/0019-5154.110832.
32. Ino H., Shiramoto M., Eto T et al. Levocetirizine Oral Disintegrating Tablet: A Randomized Open-Label Crossover Bioequivalence Study in Healthy Japanese Volunteers. Clin Pharmacol Drug Dev. 2020 Mar 20. DOI: 10.1002/cpdd.791. [Epub ahead of print].
33. Cheng Y., Lin B.J., Guo J.H. et al. The Effect Of Food On The Pharmacokinetic Properties And Bioequivalence Of Two Formulations Of Levocetirizine Dihydrochloride In Healthy Chinese Volunteers. Drug Des Devel Ther. 2019;13:3625–3634. DOI: 10.2147/DDDT.S215316.
34. Сидорович О.И. Эффективность и безопасность терапии антигистаминными препаратами у детей школьного возраста. Российский аллергологический журнал. 2019;(1):79–84. DOI: 10.36691/RAJ.2019.1-1.53228. [Sidorovich O.I. The efficacy and safety of antihistamine therapy in schoolage children. Rossiyskiy allergologicheskiy zhurnal. 2019;(1):79–84 (in Russ.)]. DOI: 10.36691/RAJ.2019.1-1.53228.
35. Астафьева Н.Г., Гамова И.В., Удовиченко Е.Н., Перфилова И.А. Левоцетиризин: современные аспекты применения при аллергических заболеваниях с точки зрения доказательной медицины. Лечащий врач. 2010:5;62–75. [Astafeva N.G., Gamova I.V., Udovichenko E.N., Perfilova I.A. Levocetirizine: current aspects of use in allergic diseases from the point of view of evidence-based medicine. Lechashchij vrach. 2010:5;62–75 (in Russ.)].
36. Bousquet J., Van Cauwenberge P., Bachert C. et al. Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI). Allergic Rhinitis and its Impact on Asthma (ARIA). Allergy. 2003;(58):192–197. DOI: 10.1034/j.1398-9995.2003.00054.x.
37. Deruaz C., Leimgruber A., Berney M. et al. Better protects than desloratadine in a nasal provocation with allergen. J Allergy Clin Immunol. 2004:(113);669–676. DOI: 10.1016/j.jaci.2004.01.773.
38. Denham K.J., Boutsiouki P., Clough G.F., Church M.K. Comparison of the effects of des-loratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. Inflamm Res. 2003;52(10):424–427. DOI: 10.1007/s00011-003-1193-5.
39. Purohit A., Melac M., Pauli G., Frossard N. Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin. Br J Clin Pharmacol. 2003;56(4):388–394. DOI: 10.1046/j.1365-2125.2003.01897.x.
40. Passalacqua G., Guerra L., Compalati E. et al. Comparison of the effects in the nose and skin of a single dose of desloratadine and levocetirizine over 24 hours. Int Arch Allergy Immunol. 2004;135(2):143–147. DOI: 10.1159/000080657.
41. Popov T.A., Dumitrascu D., Bachvarova A. et al. A comparison of levocetirizine and desloratadine in the histamine-induced wheal and flare response in human skin in vivo. Inflamm Res. 2006;55(6):241–244. DOI: 10.1007/s00011-006-0075-z.
42. Frossard N., Strolin-Benedetti M., Purohit A., Pauli G. Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine. Br J Clin Pharmacol. 2008;65(2):172–179. DOI: 10.1111/j.1365-2125.2007.03009.x.
43. Bulca S., Bayramgürler D., Odyakmaz Demirsoy E. et al. Comparison of effects of 5 and 10 mg oral desloratadine and levocetirizine on histamine-induced wheal and flare response in healthy volunteers. J Dermatolog Treat. 2013;24(6):473–476. DOI: 10.3109/09546634.2013.777152.
44. Day J.H., Briscoe M.P., Rafeiro E., Ratz J.D. Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU). Int J Clin Pract. 2004;58(2):109–118. DOI: 10.1111/j.1368-5031.2004.0117.x.
45. Ciprandi G., Cirillo I., Vizzaccaro A., Tosca M.A. Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. Clin Exp Allergy. 2004;34(6):958–964. DOI: 10.1111/j.1365-2222.2004.01960.x.
46. Lee D.K., Gardiner M., Haggart K. et al. Comparative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitis. Clin Exp Allergy. 2004;34(4):650–653. DOI: 10.1111/j.1365-2222.2004.1904.x.
47. Ciprandi G., Cirillo I., Vizzaccaro A. et al. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int Immunopharmacol. 2005;5(13–14):1800–1808. DOI: 10.1016/j.intimp.2005.05.008.
48. Инструкция по применению лекарственного препарата для медицинского применения Аллервэй. URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx? routingGuid=e56ce6e7-bc3c-45b9–986a-d9a9811c2500andt=. Дата обращения: 17.02.2020. [Instructions for use of the drug for medical use of Allerway. URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=e56ce6e7-bc3c-45b9–986a-d9a9811c2500andt=. Access date: 17.02.2020 (in Russ.)].
2. Brożek J.L., Bousquet J., Agache I. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines — 2016 revision. J Allergy Clin Immunol. 2017;140(4):950–958. DOI: 10.1016/j.jaci.2017.03.050.
3. Bousquet J., Khaltaev N., Cruz A.A. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen. Allergy. 2008;(63):8–160.
4. Gregory C., Cifaldi M., Tanner L.A. Targeted intervention programs: creating a customized practice model to improve the treatment of allergic rhinitis in a managed care population. Am J Manag Care. 1999;5:485–496.
5. Носуля Е.В., Ким И.А. Современные стратегии лечения аллергического ринита. Вестник оториноларингологии. 2016;(2):74–76. [Nosulya E.V., Kim I.A. Current treatment strategies for allergic rhinitis. Vestnik otolaringologii. 2016;(2):74–76 (in Russ.)].
6. De Greve G., Hellings P.W., Fokkens W.J. et al. Endotype-driven treatment in chronic upper airway diseases. Clin Transl Allergy. 2017;7:22. DOI: 10.1186/s13601-017-0157-8.
7. Amaral R., Fonseca J.A., Jacinto T. et al. Having concomitant asthma phenotypes is common and independently relates to poor lung function in NHANES 2007–2012. Clin Transl Allergy. 2018;8:13. DOI: 10.1186/s13601-018-0201-3.
8. Cingi C., Gevaert P., Mosges R. et al. Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology Task Force Report. Clin Transl Allergy. 2017;7:17. DOI: 10.1186/s13601-017-0153-z.
9. ARIA in the pharmacy: management of allergic rhinitis symptoms in the pharmacy. Allergic rhinitis and its impact on asthma. Allergy. 2004;59(4):373–387. DOI: 10.1111/j.1398-9995.2003.00468.x.
10. Carr W.W., Yawn B.P. Management of allergic rhinitis in the era of effective over-the-counter treatments. Postgrad Med. 2017;129(6):572–580. DOI: 10.1080/00325481.2017.1333384.
11. Lombardi C., Musicco E., Rastrelli F. et al. The patient with rhinitis in the pharmacy. A cross-sectional study in real life. Asthma Res Pract. 2015;1(1):4. DOI: 10.1186/s40733-015-0002-6.
12. Fromer L.M., Blaiss M.S., Jacob-Nara J.A. et al. Current Allergic Rhinitis Experiences Survey (CARES): Consumers’ awareness, attitudes and practices. Allergy Asthma Proc. 2014;35(4):307–315. DOI: 10.2500/aap.2014.35.3766.
13. Bousquet J., Neukirch F., Bousquet P.J. et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol. 2006;117(1):158–162. DOI: 10.1016/j.jaci.2005.09.047.
14. Bousquet J., Annesi-Maesano I., Carat F. et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin Exp Allergy. 2005;35(6):728–732. DOI: 10.1111/j.1365-2222.2005.02274.x.
15. Bousquet P.J., Devillier P., Tadmouri A. et al. Clinical relevance of cluster analysis in phenotyping allergic rhinitis in a real-life study. Int Arch Allergy Immunol. 2015;166(3):231–240. DOI: 10.1159/000381339.
16. Del Cuvillo A., Montoro J., Bartra J. et al. Validation of ARIA duration and severity classifications in Spanish allergic rhinitis patients — the ADRIAL cohort study. Rhinology. 2010;48(2):201–205. DOI: 10.4193/Rhin09.099.
17. Jauregui I., Davila I., Sastre J. et al. Validation of ARIA (Allergic Rhinitis and its Impact on Asthma) classification in a pediatric population: the PEDRIAL study. Pediatr Allergy Immunol. 2011;22(4):388–392. DOI: 10.1111/j.1399-3038.2010.01108.x.
18. Leynaert B., Bousquet J., Neukirch C. Perennial rhinitis: an independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey. J Allergy Clin. Immunol. 1999;(104):301–304. DOI: 10.1016/S0091-6749(99)70370-2.
19. Gergen P.J., Turkeltaub P.C. The association of individual allergen reactivity with respiratory disease in a national sample: data from the second National Health and Nutrition Examination Survey, 1976–80 (NHANES II). J Allergy Clin Immunol. 1992;(90):579–588. DOI: 10.1016/0091-6749(92)90130-T.
20. Pedersen P.A., Weeke E.R. Asthma and allergic rhinitis in the same patients. Allergy. 1983;(38):25–29. DOI: 10.1111/j.1398-9995.1983.tb00852.x.
21. Greisner W.A., Settipane R.J., Settipane G.A. Co-existence of asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Asthma Proc. 1998;(19):185–188. DOI: 10.2500/108854198778557836.
22. Guerra S., Sherrill D.L., Baldacci S. Rhinitis is an independent risk factor for developing cough apart from colds among adults. Allergy. 2005;(60):343–349. DOI: 10.1111/j.1398-9995.2005.00717.x.
23. Хаитов Р.М., Ильина Н.И. Аллергология и иммунология: национальное руководство. М.: ГЭОТАР-Медиа; 2009. [Haitov R.M., Il’ina N.I. Allergologija i immunologija: nacional’noe rukovodstvo. M.: GJEOTAR-Media; 2009 (in Russ.)].
24. Cauwenberge P., Bachert C., Passlacqua G. et al. Consensus statement on the treatment of allergic rhinitis. Allergy. 2000;55:116–134. DOI: 10.1034/j.1398-9995.2000.00526.x.
25. Ильина Н.И., Курбачева О.М., Павлова К.С., Польнер С.А. Федеральные клинические рекомендации. Аллергический ринит. Российский аллергологический журнал. 2018;(4):43–53. [Ilina N.I., Kurbacheva O.M., Pavlova K.S., Polner S.A. Federal Clinical Recommendations. Allergic rhinitis. Russian Journal of Allergy. 2018;(4):43–53 (in Russ.)].
26. Пискунов Г.З., Пискунов С.З. Клиническая ринология: руководство для врачей. М.: Миклош; 2002. [Piskunov G.Z., Piskunov S.Z. Clinical Rhinology: A Guide for Physicians. M.: Miklosh; 2002 (in Russ.)].
27. Лопатин А.С. Ринит. М.: Литера; 2010. [Lopatin A.S. Rhinitis. M.: Litera; 2010 (in Russ.)].
28. Bousquet J., Schünemann H.J., Hellings P.W. et al. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol. 2016;138:367–374. DOI: 10.1016/j.jaci.2016.03.025.
29. Bousquet J., van Cauwenberge P., Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001:(108);147–334. DOI: 10.1067/mai.2001.118891.
30. Лусс Л.В., Ильина Н.И. Антигистаминные препараты в общеклинической практике. Вопросы и ответы. М.: Медицинское информационное агентство; 2017. [Luss L.V., Ilyina N.I. Antihistamines in general clinical practice. Questions and answers. M.: Medical News Agency; 2017 (in Russ.)].
31. Church M., Church D. Pharmacology of antihistamines. Indian J dermatol. 2013:(58):219–224. DOI: 10.4103/0019-5154.110832.
32. Ino H., Shiramoto M., Eto T et al. Levocetirizine Oral Disintegrating Tablet: A Randomized Open-Label Crossover Bioequivalence Study in Healthy Japanese Volunteers. Clin Pharmacol Drug Dev. 2020 Mar 20. DOI: 10.1002/cpdd.791. [Epub ahead of print].
33. Cheng Y., Lin B.J., Guo J.H. et al. The Effect Of Food On The Pharmacokinetic Properties And Bioequivalence Of Two Formulations Of Levocetirizine Dihydrochloride In Healthy Chinese Volunteers. Drug Des Devel Ther. 2019;13:3625–3634. DOI: 10.2147/DDDT.S215316.
34. Сидорович О.И. Эффективность и безопасность терапии антигистаминными препаратами у детей школьного возраста. Российский аллергологический журнал. 2019;(1):79–84. DOI: 10.36691/RAJ.2019.1-1.53228. [Sidorovich O.I. The efficacy and safety of antihistamine therapy in schoolage children. Rossiyskiy allergologicheskiy zhurnal. 2019;(1):79–84 (in Russ.)]. DOI: 10.36691/RAJ.2019.1-1.53228.
35. Астафьева Н.Г., Гамова И.В., Удовиченко Е.Н., Перфилова И.А. Левоцетиризин: современные аспекты применения при аллергических заболеваниях с точки зрения доказательной медицины. Лечащий врач. 2010:5;62–75. [Astafeva N.G., Gamova I.V., Udovichenko E.N., Perfilova I.A. Levocetirizine: current aspects of use in allergic diseases from the point of view of evidence-based medicine. Lechashchij vrach. 2010:5;62–75 (in Russ.)].
36. Bousquet J., Van Cauwenberge P., Bachert C. et al. Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI). Allergic Rhinitis and its Impact on Asthma (ARIA). Allergy. 2003;(58):192–197. DOI: 10.1034/j.1398-9995.2003.00054.x.
37. Deruaz C., Leimgruber A., Berney M. et al. Better protects than desloratadine in a nasal provocation with allergen. J Allergy Clin Immunol. 2004:(113);669–676. DOI: 10.1016/j.jaci.2004.01.773.
38. Denham K.J., Boutsiouki P., Clough G.F., Church M.K. Comparison of the effects of des-loratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. Inflamm Res. 2003;52(10):424–427. DOI: 10.1007/s00011-003-1193-5.
39. Purohit A., Melac M., Pauli G., Frossard N. Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin. Br J Clin Pharmacol. 2003;56(4):388–394. DOI: 10.1046/j.1365-2125.2003.01897.x.
40. Passalacqua G., Guerra L., Compalati E. et al. Comparison of the effects in the nose and skin of a single dose of desloratadine and levocetirizine over 24 hours. Int Arch Allergy Immunol. 2004;135(2):143–147. DOI: 10.1159/000080657.
41. Popov T.A., Dumitrascu D., Bachvarova A. et al. A comparison of levocetirizine and desloratadine in the histamine-induced wheal and flare response in human skin in vivo. Inflamm Res. 2006;55(6):241–244. DOI: 10.1007/s00011-006-0075-z.
42. Frossard N., Strolin-Benedetti M., Purohit A., Pauli G. Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine. Br J Clin Pharmacol. 2008;65(2):172–179. DOI: 10.1111/j.1365-2125.2007.03009.x.
43. Bulca S., Bayramgürler D., Odyakmaz Demirsoy E. et al. Comparison of effects of 5 and 10 mg oral desloratadine and levocetirizine on histamine-induced wheal and flare response in healthy volunteers. J Dermatolog Treat. 2013;24(6):473–476. DOI: 10.3109/09546634.2013.777152.
44. Day J.H., Briscoe M.P., Rafeiro E., Ratz J.D. Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU). Int J Clin Pract. 2004;58(2):109–118. DOI: 10.1111/j.1368-5031.2004.0117.x.
45. Ciprandi G., Cirillo I., Vizzaccaro A., Tosca M.A. Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. Clin Exp Allergy. 2004;34(6):958–964. DOI: 10.1111/j.1365-2222.2004.01960.x.
46. Lee D.K., Gardiner M., Haggart K. et al. Comparative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitis. Clin Exp Allergy. 2004;34(4):650–653. DOI: 10.1111/j.1365-2222.2004.1904.x.
47. Ciprandi G., Cirillo I., Vizzaccaro A. et al. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int Immunopharmacol. 2005;5(13–14):1800–1808. DOI: 10.1016/j.intimp.2005.05.008.
48. Инструкция по применению лекарственного препарата для медицинского применения Аллервэй. URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx? routingGuid=e56ce6e7-bc3c-45b9–986a-d9a9811c2500andt=. Дата обращения: 17.02.2020. [Instructions for use of the drug for medical use of Allerway. URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=e56ce6e7-bc3c-45b9–986a-d9a9811c2500andt=. Access date: 17.02.2020 (in Russ.)].
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
